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Introduction 
Thyrotropin releasing hormone (TRH, I-pyroglutamyl-l-histidyl-l-prolin-
amide) was the fIrst hypothalamic releasing SUbstance to be isolated, 
chemically characterized and synthetized /1/. The studies to date have 
revealed that the thyrotropin release from the pituitary gland is only one of 
the numerous actions of TRH. In addition to its endocrine actions (TSH and 
prolactin release) this tripeptide has central nervous system actions totally 
unrelated to its effects on the hypothalamo-pituitary axis. This review aims to 
summarize the studies on the central nervous system' actions of TRH with 
special emphasis on the autonomic pharmacology of this peptide. 
TRH and its Receptors in the Central Nervous System 
TRH-like immunoreactivity is widely distributed throughout the whole 
nervous system of vertebrates including man, guinea pig, rat, mouse and frog. 
TRH is also present in plants and in lower animals which totally lack the 
thyroid functions. Moreover, over 70% of the total central nervous system 
TRH is located outside the hypothalamus, although the highest local 
concentrations of TRH in the brain are found in the hypothalamus and 
pituitary gland. Outside the nervous system, relatively high levels ofTRH are 
found in the gastrointestinal system (for review 1,2). 
Both hypothalamic and extrahypothalamic brain synaptosomes contain 
high amounts of TRH immunoreactivity. Furthermore, TRH has been shown 
to be present in nerve endings. In brain synaptosomes, fragments and slices, in 
vitro TRH is both released and taken up /1,2/. Furthermore, TRH was shown 
to becolocalized with neurotransmitters such as 5~hydroxytryptamine (5-HT) 
and substance P in the rat brain /3/. More recent studies indicate that TRH 
arises from the post-translational cleavage of a large precursor protein of 123 
amino acids /4/. In the rat brain both TRH and pro·TRH have been found in 
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neuronal perikarya of the parvocellular division of the paraventricular nucleus 
of the hypothalamus and the raphe complex of the medulla /5/. The 
distribution of TRH receptors is limited to relatively few tissues such as brain, 
pituitary, retina and spinal cord /1/. Burt and Snyder /6/ were the first to 
demonstrate the stereospecific binding of 3[HJ TRH to rat brain and to 
establish high and low affinity binding sites. Recently, T~-receptors have 
been shown to be present also in human brain and spinal cord /7 ,8/. 
Autoradiographic studies m: the rat brain have revealed that high levels of 
TRH receptors are found in the rhinencephalon, including accessory olfactory 
bulb, nuclei of amygdala and hippocampus; moderate to low levels we~e 
found in thalamus and hypothalamus and in most regions of the rhomb-
encephalon /9-12/. Although comparisons of the distribution of TRH 
receptors to TRH immunoreactivity indicates that in most brain areas there is 
little obvious correlation between levels of TRH peptide and its receptors, the 
extensive distribution of TRH recept~rs in the CNS provides an explanation 
for the variety of behavioral and autonomic effects observed when TRH is 
administered into the brain. 
Behavioral and Neurological Effects 
In experimental animals TRH has an an analeptic effect and antagonizes 
narcosis induced by a variety of CNS depressant agents such as ethanol, 
barbiturates and ketamine. Other tYpical effects of TRH are forepaw tremor, 
"wet dog shakes," alert appearance and overall arousal/13-15/. 
In some studies TRH has been shown to have amphetamine-like actions 
(reduction in operant tasks and eating behavior). Increased locomotor activity 
by centrally administered TRH was fust shown by Plottnikoff /16/. This 
effect is antagonized by haloperidol or pimozide /17/, suggesting that 
dopamine receptors in mesolhnbic system mediate this effect of TRH. 
However, TRH has not been shown to have any effect on dopamine or 
amphetamine induced circling behaViour in unilaterally nigrostriata11esioned 
rflts /18/. In microiontophoretic studies TRH has been reported to enhance 
the effects of acetylcholine on cortical neurons /19/. . 
The analeptic effect and arousal induced by TRH in experimental animals 
led to the hypotheSis that this peptide might have some beneficial effects in 
human depression. In the early seventies, intravenously injected TRH was 
shown to have "antidepressant" effects in human depression /20,21/. In 
experimental anim~s antidepressant drugs have been shown to cause 
increased release of TRH in brain tissue ex vivo /22/. The therapeutic activity 
of antidepressant drugs, on the other hand, has been related to their effect on 
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S·aT neurotransmission /23/. Since TRH is colocaIized with 5-HT in the 
brain and reported to have some beneficial effect on depression in man, it 
might act as a comodulator of 5·HT which causes adaptive changes in 5·HT 
neurotransmission. However, clinical investigations with TRH have attempted 
to establish its use "in depression but in no case have the results proved 
decisive /13,24/. Other mental disorders where TRH has been tried clinically 
include schizophrenia and alcohol withdrawal /13,24/. 
TRH increases skeletal muscle tonus in experimental anhnals probably by 
a direct action on spinal motor neurons /19,25/. In the rat spinal cord 
motoneurons TRH has been shown to coexist with S-HT and substance P 
/1 ,3/ and in lumbar spinal motoneurons of urethane-anesthetized rats S·HT, 
substance P and TRH were recently shown to enhance both glutamate and 
asparatate-induced excitation of the motoneurons /26/. 
Intravenously injected TRH has been proven to be of be~efit in reducing 
weakness and spasticity in motoneurone disease and in promoting recovery in 
both motoneurone disease and spinal trauma "/27-29/. These effects were 
postulated to .be mediated primarily by stimulation of TRH receptors in 
spinal cord, but spinal hypertension and increased blood flow after spinal 
injury were also suggested to contribute to the therapeutic effect of TRH. 
Other neurological disorders where TRH has been tried as treatment include 
Parkinson's disease and childhood hyperactivity with varying improvement in 
these clinical conditions /24/ . 
Thermoregulation 
Central nervous system administration of TRH or its stable analogs 
antagonizes reserpine·induced hypothermia. In intact animals, depending on 
the species, ambient temperature and the route of administration, TRH might 
produce hypothermia or hyperthermia. One of the main metabolites of TRH 
in the body,histidyl-proline.diketopiperazine, has been reported to antagonize 
the TRH-induced hyperthennia in the rat /30/. For a more detailed review 
, over the issue see Horita et al. /14/ and Metcalf /13/. 
Gastrointestinal Effects 
TRH increases colonic and duodenic activity and gastric acid secretion by 
a central nervous system activation of parasympathetic outflow. In vitro TRH 
has been shown to stimulate the guinea pig ileum and rat antrum, pylOric 
sphincter and colon but the Significance of these effects is not clear. Since 
moderate levels of TRH immunoreactivity are found in the gastrointestinal 
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system, this peptide might have a physiological role in regulation of gastric 
and intestinal motility. For further details see recent reviews by Horita et al. 
/14/, Morley /24/ and Prasad /1/. 
Respiratory Effects 
Central nervous system administration of TRH produces increases in 
, ventilatory rate /31,32/ ami respiratory minute volume with no change in 
tidal volume /31/. In halothane anesthetized rats, depletion of serotonin with 
pargyline and 5,7 -dihydroxy-tryptamine attenuated the tachypnea induced 
by TRH intracerebroventricularly (icv) as well as ne'onatal treatment with 
capsaicin or acute vagotomy in adult rats /33/. Moreover, the supersensitivity 
of serotonitl depleted rats to TRH was shown to be a result of an elevated 
PC02, thus suggesting that the respiratory responses to exogenous TRH can 
depend partly on afferent vagal input, but that other endogenous inputs to 
the respiratory center such as CO2 also contribute to the magnitude of the 
observed response by non-vagal routes. TRH immunoreactivity has been 
found in respiratory division of nucleus tractus solitarius (NTS) /34/. It was 
recently reported /35/ that in a pig brainstem preparation in vitro TRH 
induced rhythmic bursting of neurons in the respiratory division of NTS. On 
the other hand, it was shown recently that intravenous injection of TRH 
inhibited the leukotriene D4-induced bronchoconstriction in the guinea pig 
/36/. This might have some contribution to the beneficial effect of TRH in 
anaphylactic shock (see below). 
Cardiovascular Effects 
TRH has a well documented pressor effect in both experimental animals 
/32,37-40/ and in man /41-44/. In anhnals the TRH·induced increment in 
blood pressure is accompanied by a tachycardia, while in humans the heart 
rate does not significantly change after TRH .. administrations. These cardio-
vascular actions of TRH are likely to be mediated via central nervous system 
since more than a thousand fold higher doses are needed to induce 
cardiovascular changes after systemic administrations /28/ than after injections 
into the brain ventricles or distinct brain nuclei /40,45,46/. Moreover, 
transections in the cervical spinal cord abolished the pressor response to icv 
injected TRH in the rabbit, while spinal transections below T 1 had no 
influence on TRH-induced hypertensive action /38/. The pressor effect of 
TRH in leukotriene D4·induced hypotension is also totally abolished in the 
pithed rat in which the total central nervous system has been destroyed /47/. 
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The site of the cardiovascular actions of TRH in the brain is not known. 
Feuerstein and co-workers /40/ injected subnanamolar doses ofTRH into the 
nuceIus preopticus medialis (POM) of hypothalamus in the conscious rat and 
found increases in both blood pressure and heart rate. Microinjections of 
picomolar amounts of TRH into different hypothaIamic regions of halothane 
anesthetized rats were also shown to elicit moderate changes in mean arterial 
pressure and heart rate with no changes in respiratory rate or body 
temperature /45/. However, the doses of TRH used ~ these studies ar~ high 
enough to elicit increments of blood pressure and heart rate also after icv 
administration /32,46/. A recent report by Paakkari et al./48/ suggests that 
the pressor effect of TRH arises from the region of the fourth ventricle 
whereas the cardio-accelerator effect is likely to be mediated by activation of 
some fore brain structures. This suggestion is contradicted by the earlier 
fmdings /40/ that TRH, microinjected into the NTS, produced a brief 
depressor effect on blood pressure and a delayed increase in heart rate. 
Although the pressor and tachycardic effects of TRH have been well 
characterized, little is known about the hemodynamic changes mediating 
these gross cardiovascular changes. In anesthetized rabbits a systemic 
injection of TRH has been shown to increase cerebral blood flow /49/. By 
using the directional ultrasound Doppler technique we recently reported a 
differential regional blood flow pattern after both subnanomolar doses of 
TRH icy as well as by a high systemic dose /46/: The blood flow to skeletal 
muscles Significantly increased while the renal (and to a lesser degree the 
mesenteric) blood flow dose-dependently decreased after TRH injections. The 
pattern of these blood flow changes resembled those induced by intravenous 
injection of epinephrine, suggesting that these effects might be mediated by 
the activation of the sympatho-adrenomedullary axis. We have also shown 
that in the conscious rat the increase in blood pressure by TRH is likely to be 
due to an increase in cardiac output, while due to the differential blood flow 
changes the total peripheral resistance remains unchanged in intact rats /46/. 
Concomitantly with the increments in blood pressure and heart rate, TRH 
induces increase in plasma catecholamines in both animals /40,50/ and man 
/42/. These fmdings led to the suggestion that the cardiovascular effects of 
TRH are mediated by an activation of sympathetic outflow. The pressor 
effect of TRH icy in rat endotoxic shock has been shown to be abolished by 
adrenal demedullectomy /51/. In conscious intact rats the tachycardic effect 
of TRH injected into the POM was also blocked and the pressor response 
somewhat reduced in bretylium treated adrenal demedullated rats /40/. 
Studies in progress in our laboratory have shown that the renal vasoconstrictor 
response to icy or iv administered TRH is reduced to about 50% in adrenal 
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demedullated rats while the increase in skeletal muscle blood flow is blocked 
only after bretylium treatment, suggesting that both the. catecholamine 
release from adrenal medulla and the activation of sympathetic nerves 
contribute to these actions ofTRH. However, some non-adrenergic mechanisms 
are also likely to be involved in the cardiovascular actions of TRH, since its 
effects on blood pressure and heart rate were not affected by pretreatments 
with ganglion blockers, reserpine, phentolamine or propranolol/S2,38, and 
unpublished results of Our laboratory( This suggestion is further supported 
by the recent clinical fmdings that the rise in blood pressure by intravenous 
TRH in humans is not accompanied with any changes in plasma catecholamines 
/44/. Since measuring plasma catecholamines only might not be a good index 
of sympathetic tone, these fmdings do not exclude the role of sympathetic 
activation in the effects of TRH. 
In addition to the sympathetic nervous system other pressor systems have 
been :related to the cardiovascular effects of TRH. Central nervous system 
administration of TRH caused increments in plasma levels of vasopressin in 
rabbits /52,53/ but had no effect on plasma vasopressin in dogs /54/. We 
found only slight and biologically insignificant increases in plasma vasopressin 
after system administration of TRH in conscious rats. Moreover, Horita et al. 
/52/ have shown that the TRH-induced increase in vasopressin can be 
differentiated from its hypertensive effect; hexamethonium blocked the 
increment of plasma vasopressin but not the pressor response to icv 
administered TRH in anesthetized rabbits. It was recently found that the 
pressor effect of TRH icv in urethane-anesthetized rats is not blocked by a 
vasopressin antagonist /55/. 
Another pressor system which has been related to the cardiovascular 
actions of TRH is the renin-angiotensin system. The pressor effect of icv 
administered TRH was attenuated by treatment with the angiotensin 
converting enzyme inhibitor" 'captopril or with the angiotensin receptor 
antagot:list /55/. However, the endogenous renin~angiotensin system plays 
hardly any role in the effects of TRH, since administrations of this peptide to 
either humans /42/ or rats (unpublished observation of our laboratory) had 
no effect on plasma renin activity. 
TRH in Shock and Trauma 
Since TRH has been shown to be a potent cardiotonic and respiratory 
stimulator it was only natural to assume that such a compound might have 
therapeutic potential in cardiovascular states in which respiratory, cardiac or 
hemodynamic variables are severely depressed. This suggestion was further 
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supported by experiments showing that TRH effectively blocks opiates and 
opioid peptides mediated effects /56/; since activation of the endogenous 
opioid system has been argued to play an important role in cardiovascular 
depression following various shock stimuli /56/, antagonism of opioid 
mediated cardiovascular depression by TRH was considered an additional 
mechanism for the potential bene!'icial actions of TRH in shock states /56/. 
The potential therapeutic capacity of TRH was examined in several shock 
and trauma situations: hemorrhage, endotoxemia, anaphylaxis, spinal cord 
injury and multiple organ trauma. 
In hemorrhagic shock, original studies by Holaday et al. /57/ demonstrated 
that TRH can reverse the systemic hypotension produced by bleeding. The 
pressor response to TRH in hypovolemic hypotension was conflInled in other 
studies /58,59,60/. In a study conducted on anesthetized, cynomolgus 
monkeys, TRH was shown to increase myocardial contractility after 
hemorrhage /59/. Moreover, in the anesthetized rat exposed to severe 
bleeding TRH was shown to increase cardiac output along with mean arterial 
pressure /60/. However, in none of the studies cited above did TRH improve 
the survival rate of various experimental animals exposed to hemorrhagic 
shock; in a more recent study it was shown that TRH decreased the survival 
rate of conscious rats exposed to hypovolemic hypotension, a phenomenon 
most probably related to the substantial reduction in essential organ blood 
flow due to increase in vascular resistance /60/. Thus, the beneficial effect of 
TRH in hemorrhagic shock or other forms of hypovolemic hypotension is 
doubtful and extreme caution should be exercised in extrapolating the early 
reports on pressor effects of TRH in hemorrhage to therapeutic efficacy in 
both experimental animals and humans. 
A totally different form of shock is lipopolysaccharide (LPS) endotoxemia. 
In this fonn of shock the intracellular volume is primarily preserved yet 
cardiac depression, pulmonary hypertension and organ blood flow are 
severely deranged. In LPS endotoxemia, TRH was shown to produce a pressor 
response /57,61,62/. However, in this form of shock, short term survival (2 
hours) was found to be improved by TRH treatment but this effect was not 
dose dependent. In a study conducted on cynomolgus monkeys, TRH 
treatment failed to improve survival in severe endotoxemia in spite of a 
substantial pressor effect /62/. Further experiments are necessary to 
determine whether or not TRH might have a role in treatment of endotoxic 
shock. 
Anaphylactic shock is still another form of shock which is mediated by 
specific immune response cells and mediators such as leukotrienes, histamine, 
P AFacether and others (for review see 63). The anaphylactic shock is 
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characterized by severe hemodynamic derangements which include cardiac 
depression, hypotension and shock. TRH has been shown to reverse 
anaphylactic shock in the mouse /64,65/ or guinea pigs /66/; in the mouse, 
TRH substantially improved the survival rate in anaphylactic shock /64/. The 
beneficial effect of TRH in this form of shock was atrributed to central 
activation of the sympatho-adrenomeduUilIY system, primarily through 
~radrenergic receptors /64,65/. Furthermore, the therapeutic effect of TRH 
in anaphylactic shock might also be the result of improved puhnonary 
functions due to alleviation of the bronchoconstriction /36/. TRH was also 
shown to reverse the shock syndrome produced by the specific shock~ 
promoting mediators of anaphylaxis such as leukotrienes /67-69,47/ or 
platelet activating factor, PAF-acether ./70/. In both shock paradigms, which 
were conducted on conscious rats or guinea pigs, the effect of TRH on 
survival rate was not examined. Thus, more defmitive experimental work is 
necessary to determine whether TRH has significant therapeutic potential in 
immune reaction mediated shock states. 
TRH was also utilized for therapeutic trials in several traumatic injury 
models. In mUltiple trauma models of the rat, TRH was found to exacerbate 
the shock state and decrease survival rate 158/. However, in a more discrete 
model of trauma, cervical spinal cord injury, TRH was found to improve long 
term neurologic recovery /28,29/. However, additional experimental work 
would be necessary to substantiate this report, especially in more clinically 
applicable models. It should be pointed out that although TRH was found to 
reduce blood flow in essential organs of oligemic rats /60/, it was also shown 
that systemic administration of TRH to anesthetized rabbits increases blood 
flow to many brain regions /49/. Thus, it might be possible that critical levels 
of blood flow to injured eNS zones might be preserved. This suggestion is 
contradicted, however, by the fmdings that TRH had no beneficial effect on 
ischemia induced by air embolization in experhnental stroke in dogs /71/. 
In summary, although preliminary experimental work raised hopes and 
expectations for therapeutic usage of TRH in a variety of states of shock and 
trauma, the present situation is clearly controversial. 
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